Login to Your Account



Targacept, AstraZeneca Enter TC-1734 Deal For Up To $300M

By Karen Pihl-Carey


Thursday, December 29, 2005
Signing a deal worth up to $300 million for one product - and possibly more if others come into play - Targacept Inc. partnered worldwide rights to its Phase II cognitive disorder drug, TC-1734, with AstraZeneca plc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription